Lexaria Bioscience Corp.
LEXX · XNASCIK 1348362fmd_0HAD0QWYQPQE04EB2K1QGQ4Y59制造业 · 医药制剂模板: 标准
覆盖范围: 2009年8月01日 至 2026年5月31日，共 68 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| 营业成本 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 净利息收入 | – | – | – | – | – | – | – | 0 | 0 | – |
| 毛利润 | (0) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| 已实现投资收益（损失） | – | – | – | – | – | – | – | – | – | 0 |
| 研发费用 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 4 | 2 | 8 |
| 非利息收入 | – | – | – | – | – | – | 0 | 0 | – | – |
| 营业费用合计 | 1 | 2 | 7 | 4 | 4 | 6 | 7 | 7 | 6 | 13 |
| 薪酬与福利 | – | – | – | 0 | 0 | – | – | – | – | – |
| 营业利润 | (1) | (2) | (7) | (4) | (4) | (6) | (7) | (7) | (6) | (12) |
| 利息费用 | 0 | 0 | – | – | – | – | – | 0 | 0 | – |
| 其他营业外收入（支出） | – | – | – | – | – | – | (1) | (0) | (0) | (0) |
| 税前利润 | (1) | (2) | (7) | (4) | (4) | (4) | (7) | (7) | (6) | (12) |
| 所得税费用 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| 持续经营净利润 | (1) | (2) | (7) | (4) | (4) | (4) | (7) | – | – | – |
| 净利润 | (1) | (2) | 7 | 4 | (4) | (4) | (7) | (7) | (6) | (12) |
| 归属于普通股股东的净利润 | (1) | (2) | (7) | (4) | (4) | (4) | (7) | – | – | – |